{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:36:28Z","timestamp":1794969388634,"version":"4.9.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2017WXR7ZT"],"award-info":[{"award-number":["2017WXR7ZT"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clml.2022.11.011","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T02:47:03Z","timestamp":1670208423000},"page":"79-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink Treatment?"],"prefix":"10.1016","volume":"23","author":[{"given":"Barbara","family":"Mora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.11.011_bib0001","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"141","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.011_bib0002","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","article-title":"Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States","volume":"63","author":"Verstovsek","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.11.011_bib0003","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.11.011_bib0004","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.011_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00277-020-04287-w","article-title":"Is there a gender effect in polycythemia vera?","volume":"100","author":"Palandri","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.11.011_bib0006","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/leu.2011.334","article-title":"How to manage polycythemia vera","volume":"26","author":"Passamonti","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0007","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.011_bib0008","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3324\/haematol.2019.221234","article-title":"Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis","volume":"104","author":"Ferrari","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.11.011_bib0009","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.leukres.2018.04.012","article-title":"Phenotype variability of patients with post polycythemia vera and post essential thrombocythmia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia","volume":"69","author":"Mora","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.11.011_bib0011","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11899-022-00672-6","article-title":"Towards a personalized definition of prognosis in Philadelphia-negative myeloproliferative neoplasms","volume":"17","author":"Mora","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2022.11.011_sbref0012","series-title":"Myeloproliferative neoplasms, Version 3","year":"2022"},{"key":"10.1016\/j.clml.2022.11.011_bib0013","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0014","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0015","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.3324\/haematol.2017.185751","article-title":"Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project","volume":"103","author":"Mora","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.11.011_bib0016","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/ajh.25644","article-title":"Impact of bone marrow fibrosis grade in post-polycythemia vera and post essential thrombocythemia myelofibrosis: a study of the MSYEC group","volume":"95","author":"Mora","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.11.011_bib0017","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1038\/s41375-022-01673-3","article-title":"Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients","volume":"36","author":"Mora","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0018","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2016.351","article-title":"Driver mutations\u2019 effect in secondary myelofibrosis: an international multicenter study based on 781 patients","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0019","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-018-0453-y","article-title":"Post-ET and post-PV myelofibrosis: updates on a distinct prognosis from primary myelofibrosis","volume":"13","author":"Passamonti","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2022.11.011_bib0020","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0021","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.11.011_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106809","article-title":"Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia","volume":"115","author":"Pemmaraju","year":"2022","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.11.011_bib0023","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"7","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0024","series-title":"Annual Meeting","article-title":"Mortality and causes of death of patients with polycythemia vera: analysis of the REVEAL prospective, observational study","author":"Stein","year":"2021"},{"key":"10.1016\/j.clml.2022.11.011_bib0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.11.011_bib0026","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/s41375-018-0199-5","article-title":"Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0027","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/794240","article-title":"The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera","volume":"2011","author":"Marchioli","year":"2011","journal-title":"Thrombosis"},{"key":"10.1016\/j.clml.2022.11.011_bib0028","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","article-title":"White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study","volume":"126","author":"Barbui","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.011_bib0029","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood.2020008043","article-title":"Clinical insights into the origins of thrombosis in myeloproliferative neoplasms","volume":"137","author":"Moliterno","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.011_bib0030","series-title":"Annual Meeting","article-title":"A real-world evaluation of the association between elevated blood counts and thrombotic events in polycythemia vera (analysis of data from the REVEAL study)","author":"Gerds","year":"2021"},{"key":"10.1016\/j.clml.2022.11.011_bib0031","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.11.011_bib0032","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.11.011_bib0033","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41408-022-00625-5","article-title":"Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera","volume":"12","author":"Carobbio","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.11.011_bib0034","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1002\/ajh.26423","article-title":"Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia","volume":"97","author":"Farrukh","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.11.011_bib0035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/th15-04-0326","article-title":"Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment","volume":"115","author":"De Stefano","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2022.11.011_bib0036","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1038\/s41375-021-01279-1","article-title":"Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0037","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-alpha therapy in BCR-ABL-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0038","first-page":"17","article-title":"From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2022.11.011_bib0039","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.24851","article-title":"A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.11.011_bib0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.11.011_bib0041","series-title":"Annual Meeting","article-title":"Interactions of key hematological parameters with red cell distribution width (RDW) are associated with incidence of thromboembolic events (TEs) in polycythemia vera (PV) patients: a machine learning study (PV-AIM)","author":"Verstovsek","year":"2020"},{"key":"10.1016\/j.clml.2022.11.011_bib0042","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-017-0038-3","article-title":"Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data","volume":"8","author":"Ghirardi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.11.011_bib0043","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0044","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/imj.14154","article-title":"Recommendations for the use of pegylated interferon-\u03b1 in the treatment of classical myeloproliferative neoplasms","volume":"49","author":"Forsyth","year":"2019","journal-title":"Intern Med J"},{"key":"10.1016\/j.clml.2022.11.011_bib0045","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.011_bib0046","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.11.011_bib0047","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0048","series-title":"Annual Meeting","article-title":"Ropeginterferon alfa-2b achieves patient-specific treatment goals in polycythemia vera: final results from the PROUD-PV\/CONTINUATION-PV studies","author":"Gisslinger","year":"2022"},{"key":"10.1016\/j.clml.2022.11.011_bib0049","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.011_bib0050","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41375-021-01447-3","article-title":"Normal life expectancy for polycythemia vera (PV) patients is possible","volume":"36","author":"Abu-Zeinah","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.11.011_bib0051","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"Barosi","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.11.011_bib0052","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjh.13886","article-title":"Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera","volume":"172","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.11.011_bib0053","series-title":"Annual Meeting","article-title":"Clinical outcomes under hydroxyurea and impact of ELN responses in patients with polycythemia vera: a PV-NET real world study","author":"Palandri","year":"2019"},{"key":"10.1016\/j.clml.2022.11.011_bib0054","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2016.152769","article-title":"Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea","volume":"102","author":"Alvarez-Larr\u00e1n","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.11.011_bib0055","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.3324\/haematol.2017.165126","article-title":"No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials","volume":"102","author":"Barbui","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.11.011_bib0056","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"et al. N Engl J Med"},{"key":"10.1016\/j.clml.2022.11.011_bib0057","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib. Versus best available therapy in polycythemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.11.011_bib0058","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.11.011_bib0059","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00277-018-3365-y","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial","volume":"97","author":"Griesshammer","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.11.011_bib0060","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","article-title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","volume":"9","author":"Passamonti","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.11.011_bib0061","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.3390\/cancers12113132","article-title":"Ruxolitinib-associated infections in Polycythemia vera: review of the literature, clinical significance, and recommendations","volume":"12","author":"Sadjadian","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2022.11.011_bib0062","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1002\/cam4.2107","article-title":"Second primary malignancies in postpoylycythemia vera and postessential thrombocythemia myelofibrosis: a study on 2233 patients","volume":"8","author":"Mora","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2022.11.011_bib0063","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.011_bib0064","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/bloodadvances.2019001158","article-title":"Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis","volume":"4","author":"Masciulli","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.11.011_bib0065","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/cncr.34195","article-title":"Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance\/intolerance to hydroxyurea","volume":"128","author":"Alvarez-Larr\u00e1n","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.11.011_bib0066","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2018893545","article-title":"Oral idasanutlin in patients with polycythemia vera","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.011_bib0067","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/bloodadvances.2021006043","article-title":"The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study","volume":"6","author":"Mascarenhas","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.11.011_bib0068","series-title":"Annual Meeting","article-title":"Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients","author":"Hoffman","year":"2022"},{"key":"10.1016\/j.clml.2022.11.011_bib0069","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arteial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcranz","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2022.11.011_bib0070","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502201744X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502201744X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:40Z","timestamp":1761871300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502201744X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S215226502201744X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.11.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink Treatment?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}